Home
AI
World
Politics
Health
Crime & justice
Science & technology
Social issues
Sports
Money
Entertainment
Environment/energy
Military
Culture
Weather
Media






Home
Bias Split
Public FiguresControversies

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters

Sign Up!
Sign Up Now!

How our sliders workAboutContact UsNewsletter Archive
MediaFAQGlossaryPrivacy Policy
  1. Home

Moderna, Merck Vaccine Combo Cuts Melanoma Recurrence

  • #COVID-19
  • #Medicine & healthcare
  • #Vaccination
  • #Cancer
  • #Diseases & conditions
story
DEC 2022
Image copyright: AP [via The Wall Street Journal]
story last updated DEC 2022

The Spin

Narrative A

Cancer vaccine research hasn't been very successful due to cycle times taking too long, which is why this study is such a breakthrough. The use of mRNA technology not only allows a quicker process but a personalized one in which individual patients' tumor DNA can be used to attack specific cancer cell mutations harming their immune systems.

Washington Post

Narrative B

This is all positive news, but we shouldn't get ahead of ourselves over just one headline. While promising, potentially successful cancer vaccines like this face many challenges and are still years away from being rolled out. Further research is needed.

Frontiers

Articles on this story

Cancer vaccine could be available by 2030, COVID vax-makers say
New York PostJUL 2022
FDA Authorizes Novavax Covid-19 Shot as Booster for Adults
Wall Street JournalJUL 2022